Dallas
, Texas
- D. Anderson Company (DAC), an international patient recruitment and retention leader based in Dallas, posted a record first quarter on many fronts, including earnings, new business and requests for proposals. The privately held company, whose clientele is a who's who in pharmaceuticals and biotechnology, enters the second quarter brimming with optimism as contracts continue to outpace previous years.
Central to DAC's success is its growth in global markets and its ability to leverage 18 years of experience, including tenure as a Site Management Organization, niche Contract Research Organization and clinical trials recruitment provider.
"In 2007 and 2008, the percent of DAC's business with international focus was 40 and 48 percent respectively for the entire year," said DAC President and CEO Diana Anderson, Ph.D. "Already, in 2009, half of new contracts are for global programs, with the remaining focused on North America. Large pharmaceutical companies represent 66 percent of new business so far this year."
Dr. Anderson has positioned DAC as an international player with experience in 62 countries and expertise in more than 40 therapeutic areas. The company has strong roots in rheumatology but, today, draws most of its business from the oncology, cardiovascular, central nervous system, and immunology sectors.
DAC services include patient recruitment and retention, consulting, management, market research and customized training. With its full-service, in-house creative agency, DAC also combines messaging, design and branding to produce acclaimed marketing concepts.
About D. Anderson Company
With offices in Seattle, Houston and Dallas, DAC is a subsidiary of D.L. Anderson International. The company is certified as a Women-Owned Business (WBE) by the Women's Business Enterprise National Council and a continuing education provider through the California Board of Registered Nursing. For more information, visit
www.dandersoncompany.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.